Literature DB >> 1946464

Identification of the staphylococcal enterotoxin A superantigen binding site in the beta 1 domain of the human histocompatibility antigen HLA-DR.

A Herman1, N Labrecque, J Thibodeau, P Marrack, J W Kappler, R P Sekaly.   

Abstract

The staphylococcal enterotoxin A (SEA) is a superantigen that must bind to class II molecules of the major histocompatibility complex to be recognized by T cells. In humans, most HLA-DR class II allelic and isotypic forms, such as DR1, bind SEA well. DRw53 is an exception, binding SEA very poorly. We have localized this difference to a single residue (amino acid 81) in the beta 1 domain. A highly conserved histidine at residue 81 allows SEA binding, but a tyrosine does not. Residue 81 is predicted to lie in an alpha-helix on the surface of the molecule, with its side chain pointing up out of the pocket associated with binding of conventional peptide antigens. This finding supports the hypothesis that superantigens and conventional antigens bind to different sites on the class II molecule.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1946464      PMCID: PMC52845          DOI: 10.1073/pnas.88.22.9954

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

Review 1.  Superantigens: mechanism of T-cell stimulation and role in immune responses.

Authors:  A Herman; J W Kappler; P Marrack; A M Pullen
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

2.  Structural basis for differential binding of staphylococcal enterotoxin A and toxic shock syndrome toxin 1 to class II major histocompatibility molecules.

Authors:  C H Pontzer; J K Russell; H M Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

3.  Staphylococcal exotoxin activation of T cells. Role of exotoxin-MHC class II binding affinity and class II isotype.

Authors:  J A Mollick; M Chintagumpala; R G Cook; R R Rich
Journal:  J Immunol       Date:  1991-01-15       Impact factor: 5.422

4.  The mitogenic effects of endotoxin and staphylococcal enterotoxin B on mouse spleen cells and human peripheral lymphocytes.

Authors:  D L Peavy; W H Adler; R T Smith
Journal:  J Immunol       Date:  1970-12       Impact factor: 5.422

5.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

6.  Superantigens interact with MHC class II molecules outside of the antigen groove.

Authors:  P Dellabona; J Peccoud; J Kappler; P Marrack; C Benoist; D Mathis
Journal:  Cell       Date:  1990-09-21       Impact factor: 41.582

7.  A superantigen encoded in the open reading frame of the 3' long terminal repeat of mouse mammary tumour virus.

Authors:  Y Choi; J W Kappler; P Marrack
Journal:  Nature       Date:  1991-03-21       Impact factor: 49.962

8.  An endogenous retrovirus mediating deletion of alpha beta T cells?

Authors:  D L Woodland; M P Happ; K J Gollob; E Palmer
Journal:  Nature       Date:  1991-02-07       Impact factor: 49.962

9.  Clonal deletion of V beta 14-bearing T cells in mice transgenic for mammary tumour virus.

Authors:  H Acha-Orbea; A N Shakhov; L Scarpellino; E Kolb; V Müller; A Vessaz-Shaw; R Fuchs; K Blöchlinger; P Rollini; J Billotte
Journal:  Nature       Date:  1991-03-21       Impact factor: 49.962

10.  HLA-DR alleles differ in their ability to present staphylococcal enterotoxins to T cells.

Authors:  A Herman; G Croteau; R P Sekaly; J Kappler; P Marrack
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

View more
  41 in total

1.  Distinct binding sites on HLA-DR for invariant chain and staphylococcal enterotoxins.

Authors:  D R Karp; R N Jenkins; E O Long
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

2.  Relative abilities of distinct isotypes of human major histocompatibility complex class II molecules to bind streptococcal pyrogenic exotoxin types A and B.

Authors:  K Imanishi; H Igarashi; T Uchiyama
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

Review 3.  The potential role of superantigens in inflammatory bowel disease.

Authors:  R A Kay
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

4.  Functional analysis of Mycoplasma arthritidis-derived mitogen interactions with class II molecules.

Authors:  C Bernatchez; R Al-Daccak; P E Mayer; K Mehindate; L Rink; S Mecheri; W Mourad
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

5.  Selective binding of bacterial toxins to major histocompatibility complex class II-expressing cells is controlled by invariant chain and HLA-DM.

Authors:  P M Lavoie; J Thibodeau; I Cloutier; R Busch; R P Sékaly
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

Review 6.  Genetically engineered superantigens in experimental tumor therapy.

Authors:  P Antonsson; J Hansson; T Kalland; P A Lando; L Ohlsson; E Schad; A Svensson; M Dohlsten
Journal:  Springer Semin Immunopathol       Date:  1996

Review 7.  Evidence for a superantigen in the pathogenesis of tuberculosis.

Authors:  J D Ohmen; R L Modlin
Journal:  Springer Semin Immunopathol       Date:  1996

8.  Biochemical and mutational analysis of the histidine residues of staphylococcal enterotoxin A.

Authors:  M Hoffman; M Tremaine; J Mansfield; M Betley
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

9.  Superantigen staphylococcal enterotoxin B-induced T-helper cell activation is independent of CD4 molecules and phosphatidylinositol hydrolysis.

Authors:  N Oyaizu; N Chirmule; H Yagura; R Pahwa; R A Good; S Pahwa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

10.  Staphylococcal enterotoxin A induces small clusters of HLA-DR1 on B cells.

Authors:  Kedar Narayan; Edward M Perkins; Gavin E Murphy; Sarat K Dalai; Michael Edidin; Sriram Subramaniam; Scheherazade Sadegh-Nasseri
Journal:  PLoS One       Date:  2009-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.